IMMUNOLOGY

免疫学

• 批准号: 6563638
• 负责人: ALAN N. HOUGHTON
• 金额: $ 15.75万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-01-30 至 2002-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6563638
• 关键词: T cell receptor; T lymphocyte; apoptosis; biological signal transduction; bone marrow transplantation; cell differentiation; graft versus host disease; immunodeficiency; immunogenetics; major histocompatibility complex; neoplasm /cancer immunology

Description: The Immunology Program consists of 12 members with research interests in basic and clinical immunology, including a strong emphasis on the application of basic immunologic findings to the treatment of hematopoietic malignancies and solid tumors. Several laboratories pursue fundamental studies in murine lymphocyte biology and genetics. Dr. Ulrich Hammerling has contributed to murine immunogenetics and the characterization of human cell surface antigens, and has recently been focusing on the role of vitamin A in lymphocyte metabolism and immunodeficiency. Dr. Janko Nikolic-Zugic studies the developmental biology of murine thymocytes, with a particular emphasis on the role of T-cell receptor alpha rearrangements in thymic selection and apoptosis. Dr. Howard Petrie (recruited as a new assistant member in the Immunology Program in 1993) investigates the membrane events and signaling pathways that influence differentiation, cell division, and programmed cell death in murine thymocyte development. Dr. Osias Stutman continues to study cell-mediated immune responses and the immunologic function of tumor necrosis factor. Several investigators have interests in the immunogenetics of the human major histocompatibility complex (MHC). Dr. Janet Lee is studying an immunodeficiency disease designated the Bare Lymphocyte Syndrome, as a model for understanding transcriptional regulation of MHC class II molecules. Dr. Soo Young Yang is investigating the alloreactivity responsible for graft failure or graft-versus-host disease, and is also identifying DNA binding proteins that regulate class I transcription, and evaluating fine genetic polymorphisms in MHC class I and class II genes. Dr. Bo Dupont has made many contributions to the immunogenetics of the human MHC. He also has a current effort dedicated to understanding the regulation and function of CD28/B7 costimulation in T-cell responses. Several Immunology Program members work at an interface between translational research and clinical application, and employ immunologic strategies to treat hematopoietic malignancies by bone marrow transplantation (BMT), and to treat solid tumors with monoclonal antibodies and cytokines. Dr. Richard O'Reilly studies the immunobiology of bone marrow transplantation, and directs the pediatric BMT unit that treats leukemia and congenital immunodeficiencies. A second new addition to the Immunology Program (a joint recruitment with Cancer Prevention and Control), Dr. Michel Sadelain, brings expertise in the construction and use of retroviral vectors for gene therapy. Cancer Immunology is an area of considerable emphasis and tradition. Dr. Lloyd Old continues to study cell surface antigens on murine and human tumors, with the intent of developing immunologic approaches to treating human cancer. Dr. Alan Houghton, Program Head, has a major emphasis on identifying peptide sequences that stimulate the host immune response to tumors (particularly melanoma), and the development of human cancer vaccines. Dr. Kenneth Lloyd conducts fundamental biochemical analysis of glycoproteins and glycolipids, with a particular emphasis on defining the immunogenicity of gangliosides and blood group antigens on human solid tumors. Ten of the twelve Immunology Program members have NIH support, and the group has a total of nine R01s and two R29s. Furthermore, Drs. O'Reilly and Houghton are principal investigators on NCI program projects. The program makes extensive use of Center shared resources.

描述：免疫学项目由 12 名从事研究的成员组成 对基础和临床免疫学的兴趣，包括强烈强调 基本免疫学发现在造血系统治疗中的应用 恶性肿瘤和实体瘤。多个实验室致力于基础研究 小鼠淋巴细胞生物学和遗传学研究。乌尔里希·哈默林 (Ulrich Hammerling) 博士 对鼠免疫遗传学和人类细胞的表征做出了贡献 表面抗原，最近一直关注维生素 A 在 淋巴细胞代谢和免疫缺陷。 Janko Nikolic-Zugic 博士的研究 小鼠胸腺细胞的发育生物学，特别强调 T细胞受体α重排在胸腺选择中的作用和 细胞凋亡。 Howard Petrie博士（被聘为新助理会员） 1993 年免疫学计划）研究膜事件和信号传导 影响分化、细胞分裂和程序化细胞的途径 小鼠胸腺细胞发育过程中的死亡。 Osias Stutman 博士继续研究 细胞介导的免疫反应和肿瘤坏死的免疫功能 因素。一些研究人员对免疫遗传学感兴趣 人类主要组织相容性复合体 (MHC)。 Janet Lee 博士正在研究 免疫缺陷疾病被指定为裸淋巴细胞综合征，作为模型 用于了解 MHC II 类分子的转录调控。博士。 Soo Young Yang 正在调查导致移植的同种异体反应性 失败或移植物抗宿主病，并且还识别 DNA 结合 调节 I 类转录的蛋白质，并评估精细遗传 MHC I 类和 II 类基因的多态性。 Bo Dupont 博士做了很多 对人类 MHC 免疫遗传学的贡献。他还有一个当前 致力于了解 CD28/B7 共刺激的调节和功能的努力 在 T 细胞反应中。 一些免疫学计划成员在翻译和免疫学之间的接口上工作 研究和临床应用，并采用免疫策略来治疗 通过骨髓移植（BMT）治疗造血系统恶性肿瘤 具有单克隆抗体和细胞因子的实体瘤。理查德·奥莱利博士 研究骨髓移植的免疫生物学，并指导 治疗白血病和先天性免疫缺陷的儿科 BMT 单位。一个 免疫学项目的第二个新成员（与癌症联合招募 预防和控制），米歇尔·萨德兰博士带来了以下领域的专业知识 用于基因治疗的逆转录病毒载体的构建和使用。癌症 免疫学是一个非常受重视和传统的领域。劳埃德·奥德博士 继续研究小鼠和人类肿瘤的细胞表面抗原， 旨在开发治疗人类癌症的免疫方法。博士。 Alan Houghton，项目负责人，重点关注肽的识别 刺激宿主对肿瘤的免疫反应的序列（特别是 黑色素瘤），以及人类癌症疫苗的开发。肯尼思·劳埃德博士 对糖蛋白和糖脂进行基础生化分析， 特别强调定义神经节苷脂的免疫原性和 人类实体瘤的血型抗原。 十二个免疫学计划成员中有十个得到了 NIH 的支持，并且该小组 共有九辆R01和两辆R29。此外，博士。奥莱利和 霍顿是 NCI 项目的主要研究员。该计划 广泛利用中心共享资源。